Sativex®
Sponsors
Jazz Pharmaceuticals, Almirall, S.A.
Conditions
CancerDetrusor OveractivityDiabetesMultiple SclerosisNeuropathic PainPainPalliative CarePeripheral Neuropathy
Phase 3
A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy
CompletedNCT00674609
Start: 2002-02-28End: 2004-03-31Updated: 2023-05-03
A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple Sclerosis
CompletedNCT00678795
Start: 2002-08-31End: 2005-10-31Updated: 2023-05-03
A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)
CompletedNCT00681538
Start: 2008-01-31End: 2009-01-31Updated: 2023-05-06
A Study of Sativex® for Relief of Peripheral Neuropathic Pain Associated With Allodynia.
CompletedNCT00711880
Start: 2002-05-31End: 2004-03-31Updated: 2023-04-12
A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis.
CompletedNCT00711646
Start: 2002-06-30End: 2004-03-31Updated: 2023-05-06
A Study to Compare the Safety and Tolerability of Sativex® in Patients With Neuropathic Pain.
CompletedNCT00713323
Start: 2005-10-31End: 2007-06-30Updated: 2023-05-03
A Study to Determine the Maintenance of Effect After Long-term Treatment of Sativex® in Subjects With Neuropathic Pain
CompletedNCT00713817
Start: 2007-03-31End: 2007-07-31Updated: 2023-05-03
Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity
CompletedNCT01538225
Start: 2012-04-30End: 2013-11-30Updated: 2014-01-20